Enzo Biochem, Inc. v. Applera Corp.

243 F.R.D. 45, 2007 U.S. Dist. LEXIS 57072, 2007 WL 2248040
District Court, D. Connecticut·Decided August 3, 2007·No. No. 3:04cv929 (JBA)·Published·Cited by 3 cases

Opinion

RULING ON DEFENDANTS’ MOTION FOR LEAVE TO FILE FIRST AMENDED ANSWER [DOC. # 186]

ARTERTON, District Judge.

On June 7, 2004, plaintiffs Enzo Biochem, Inc., Enzo Life Sciences, Inc., and Yale University (collectively “Enzo”) brought this suit for patent infringement against defendants Applera Corp. and Tropix, Inc. (collectively “Applera”). Defendants’ Answer and Counterclaims [Doc. # 13] were filed on July 29, 2004, and plaintiffs’ Reply [Doc. # 17] was filed August 23, 2004.

Pursuant to Fed.R.Civ.P. 15(a), defendants now move for leave to file an amended answer that adds two affirmative defenses (patent misuse and unclean hands), an additional paragraph on patent misuse under Counterclaim One, and, as part of the relief sought, a declaratory judgment that the Ward Patents are unenforceable [Doc. # 186]. For the reasons that follow, defendants’ Motion is DENIED.

[47]*47I. Relevant Procedural Background

Plaintiffs bring 12 counts of infringement which defendants deny and in response assert four affirmative defenses: failure to state a claim upon which relief can be granted, invalidity, laches, and estoppel, as well as counterclaims for a declaratory judgment of non-infringement and invalidity as to three patents. Defendants have not previously sought to amend their answer.

In defendants’ supplemental response dated May 17, 2005 to plaintiffs’ interrogatory asking defendants to “detail all facts and identify all documents that Defendants contend support or tend to support its [sic] defenses, affirmative defenses and counterclaims,” Applera stated that it was relying only on “the equitable doctrines of laches and/or equitable estoppel,” and in response to another interrogatory, defendants “state[d] that they d[id] not at th[at] time allege that the Patents-in-Suit are unenforceable.” (Supplem. Interrog. Responses Nos. 6, 11, Pis. Ex. 5 (under seal).) On September 30, 2005, Applera sent its proposed amended answer to plaintiffs adding the affirmative defenses of “misuse” and “inequitable conduct” and demands for declaratory judgments as to the unenforceability of the Ward and Stavrianopoulos Patents (Defs. Ex. 4), seeking but not obtaining plaintiffs’ consent.

Several months later, in a Mediation Statement dated February 6, 2006, defendants described their position on “Unclean Hands” (Pis. Ex. 2 (under seal)), which they substantially repeated in their “Supplemental Response to Plaintiffs Interrogatory No. 6,” dated March 6, 2007 (Pis. Ex. 3 (under seal)). On December 21, 2006, defendants sent plaintiffs a second proposed amended answer that is identical to the one defendants now seek leave to file. (Defs. Ex. 10.) The parties dispute when plaintiffs refused to consent to this second proposed pleading: after a telephonic conference between the parties on February 20, 2007, defendants memorialized by letter to plaintiffs that although plaintiffs had “explained that Enzo [would] not consent to the filing of the Amended Answer [dated December 21, 2006], and that [Enzo] previously communicated this to [defendants’ counsel] Peter Sandel,” “Mr. Sandel has no recollection of that conversation.” (Defs. Ex. 11.) In response, plaintiffs’ counsel wrote on February 21, 2007: “My recollection is in each instance when which [sic] Applera has requested to Amend the Answer or Counterclaim, Plaintiffs have made clear that it [sic] would not consent to any such proposed Amendment, particularly at this late stage in discovery.” (Defs. Ex. 2.)

In the parties’ joint motion for pre-filing conference [Doc. # 163], defendants “advise[d] the Court that [they would] shortly file a motion under Rule 15 of the Federal Rules of Civil Procedure seeking leave to amend [the] Answer.” When this topic was discussed at the conference on February 27, 2007, plaintiffs stated their opposition, and the Court set down a schedule for briefing.

II. Standard

Under Fed.R.Civ.P. 15(a), “a party may amend [its] pleading ... by leave of court ... and leave shall be freely given when justice so requires.” “[I]t is within the sound discretion of the district court to grant or deny leave to amend.... A district court has discretion to deny leave for good reason, including futility, bad faith, undue delay, or undue prejudice to the opposing party.” McCarthy v. Dun & Bradstreet Corp., 482 F.3d 184, 200 (2d Cir.2007). In the Second Circuit, “[t]he rule ... has been to allow a party to amend its pleadings in the absence of a showing by the nonmovant of prejudice or bad faith____ However, ‘the longer the period of an unexplained delay, the less will be required of the nonmoving party in terms of a showing of prejudice.’ ” Block v. First Blood Assocs., 988 F.2d 344, 350 (2d Cir. 1993).

III. Discussion

Defendants seek to add the following paragraphs to their Answer:

106. Plaintiffs’ claims of infringement of the Ward Patents are barred, inter alia, by the doctrine of patent misuse.
107. Plaintiffs’ claims of infringement of the Ward Patents are barred, inter [48]*48alia, by the equitable doctrine of unclean hands.
124. The Ward Patents are unenforceable due to patent misuse.
(WHEREFORE, Applera and Tropix respectfully request a judgment against Enzo Biochem, Enzo Life Sciences, and Yale as follows: ...)
I. that the Court enter a declaratory judgment that each of the Ward Patents is unenforceable.

(Proposed Am. Ans., Defs. Ex. 1, at 12, 14, 17.)

A. Undue Delay

While acknowledging that their Motion for Leave to Amend was filed more than two and a half years after their original Answer, defendants contend that this delay is not prejudicial and resulted from plaintiffs’ tardiness in complying with discovery demands. Defendants also maintain that they only had enough information to add the proposed affirmative defenses after the January 2007 depositions of Rule 30 witnesses Dean Engelhardt and Ronald Fedus and the February 2007 deposition of Elazar Rabbani. Plaintiffs argue that the delay is inexcusable because defendants represented as early as August 2004 their intention to take discovery on patent misuse and had framed their unclean hands argument by February 2006, and that at the very latest, defendants could have sought leave to amend by mid-January 2007. With respect to the patent misuse defense, plaintiffs also assert that as of 1995 defendants were aware of the types of business agreements Enzo had with Yale and other entities.

“Where considerable time has elapsed between the filing of the complaint and the motion to amend, the moving party has the burden to provide a satisfactory explanation for the delay.” Messier v. Southbury Training Sch., No. 3:94-CV-1706 (EBB), 1999 WL 20907, at *3,1999 U.S. Dist. Lexis 6992, at *8 (D.Conn. Jan.

Free access — add to your briefcase to read the full text and ask questions with AI

Enzo Biochem, Inc. v. Applera Corp., 243 F.R.D. 45, 2007 U.S. Dist. LEXIS 57072, 2007 WL 2248040 (D. Conn. 2007).

243 F.R.D. 45 (Enzo Biochem, Inc. v. Applera Corp.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related